A new partnership in China will see German generics drugmaker STADA Arzneimittel (SAZ: Xetra) expand and bolster its distribution and promotion of cough and cold brands in the country.
The Bad Vilbel-based company has agreed terms for a collaboration with locally-listed pharmaceuticals firm CR Sanjiu.
Following a formal signing ceremony held in Shenzhen, CR Sanjiu has taken on responsibility for the hospital, pharmacy and e-commerce channel distribution and promotion of STADA's products in this area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze